ANDI Andiamo Corporation (CE)

New York, NY -- March 18, 2018 -- InvestorsHub NewsWire -- Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on the following public companies.
 
Andiamo Corporation (OTCBB: ANDI), and its subsidiary Utopya are coming to market with a new and exciting smart phone, the Utopya Odyssey for Android. This 4G smartphone features an incredible 4950 mAh battery, a beautiful 6" FHD 18:9 display, dual SIM card functionality, up to 192 GB storage capacity.
Get the full research report here with no obligation by clicking the following secure link- https://secure.blueoctane.net/forms/03RHO6GWLNP8
 
Celebrity Nick Cannon is the Chief Strategy Officer of nFusz, Inc. (OTCQB: FUSZ), a Hollywood-based digital tech company. They have developed proprietary interactive video technology which serves as the basis for certain products and services they market under the brand name “notifi”. notifiCRM, notifiADS, notifiLINKS, and notifiWEB products are cloud-based, software-as-a-service (“SaaS”), customer relationship management (“CRM”), sales lead generation, advertising and social engagement software.

Get the full research report here with no obligation by clicking the following secure link- https://secure.blueoctane.net/forms/03RHO6GWLNP8
 
Currently making moves into the hospital business, Rennova Health, Inc. (OTCQB: RNVA) is a vertically integrated Public Company that provides industry leading Diagnostics and supportive software solutions to healthcare providers. Last year the company acquired a Tennessee hospital and they are preparing to close on another, just 38 miles from the previous one.
Get the full research report here with no obligation by clicking the following secure link- https://secure.blueoctane.net/forms/03RHO6GWLNP8
 
Northwest Biotherapeutics, Inc. (OTCQB: NWBO) is a development stage biotechnology company. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines.  The Company's lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most aggressive and lethal form of brain cancer and is an "orphan disease."  The Company is also pursuing a Phase I/II trial with DCVax-Direct for all types of inoperable solid tumor cancers. 
Get the full research report here with no obligation by clicking the following secure link- https://secure.blueoctane.net/forms/03RHO6GWLNP8
 
Disclosure
 
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
 
TNS LLC has not been compensated; directly or indirectly; for producing or publishing this document.
 
PRESS RELEASE PROCEDURES
 
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
 
NO WARRANTY
 
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
 
NOT AN OFFERING
 
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.
 
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com
 
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT:
editor@tradersnewssource.com
SOURCE: Traders News Source

Andiamo (CE) (USOTC:ANDI)
Historical Stock Chart
From Oct 2024 to Nov 2024

Andiamo (CE) (USOTC:ANDI)
Historical Stock Chart
From Nov 2023 to Nov 2024